Table 2. Treatment upon first progression.
|
CAIRO3 |
AIO 0207 |
|||||
|---|---|---|---|---|---|---|
| Observation (n=279) | FP+Bev (n=278) | Total (n=557) | Observation (n=158) | FP+Bev (n=156) | Total (n=314) | |
| Anti-EGFR therapy | 48 (17) | 54 (19) | 102 (18) | 40 (25) | 44 (28) | 84 (27) |
| Irinotecan | 165 (59) | 162 (58) | 327 (59) | 96 (61) | 85 (54) | 181 (58) |
| Mitomycin | 1 (0.4) | 1 (0.4) | 2 (0.4) | 13 (8) | 13 (8) | 26 (8) |
| Regorafenib | 2 (0.7) | 1 (0.4) | 3 (0.5) | 9 (6) | 13 (8) | 22 (7) |
| Aflibercept/placeboa | 8 (3) | 4 (1.4) | 12 (2) | 12 (8) | 6 (4) | 18 (6) |
| Ramucirumab/placebo | 2 (0.7) | 2 (0.7) | 4 (0.7) | 1 (1) | 2 (1) | 3 (1) |
| Tegafur-uracil | 3 (1) | 5 (2) | 8 (1) | — | — | — |
| Cisplatin | 1 (0.4) | — | 1 (0.2) | — | — | — |
| Paclitaxel | — | 1 (0.4) | 1 (0.2) | — | — | — |
| Experimental study drug | 9 (3) | 4 (1) | 13 (2) | — | 1 (1) | 1 (0.3) |
| Dendritic cell vaccinations | 1 (0.4) | — | 1 (0.2) | — | — | — |
| No other agent than FP, Ox, Bev | 104 (37) | 101 (36) | 205 (37) | 60 (38) | 65 (42) | 125 (40) |
Abbreviations: Bev=bevacizumab; FP=fluoropyrimidine; Ox=oxaliplatin.
The data are n (%) unless otherwise specified.
a
No placebo for AIO 0207.